| pubmed-article:16337243 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16337243 | lifeskim:mentions | umls-concept:C0021289 | lld:lifeskim |
| pubmed-article:16337243 | lifeskim:mentions | umls-concept:C0039005 | lld:lifeskim |
| pubmed-article:16337243 | lifeskim:mentions | umls-concept:C0003842 | lld:lifeskim |
| pubmed-article:16337243 | lifeskim:mentions | umls-concept:C0042402 | lld:lifeskim |
| pubmed-article:16337243 | pubmed:issue | 23 | lld:pubmed |
| pubmed-article:16337243 | pubmed:dateCreated | 2006-4-24 | lld:pubmed |
| pubmed-article:16337243 | pubmed:abstractText | Urotensin-II (UT-II) is a small circular peptide and is described as the most potent endogenous vasoconstrictor in various vascular beds. However, the in vivo effects of UT-II can be either vasoconstriction or vasodilation depending on the species and the tissue investigated. The present study sought to characterize the vasoactive effect of UT-II in the piglet cerebral circulation in vivo. Pial arteries of 99 +/- 6 microm were visualized with intravital microscopy through a closed cranial window in anesthetized newborn piglets. Topical application of UT-II elicited a weak dose-dependent vasodilation of the arteries (0.001 microM: 3 +/- 3 microm, 0.1 microM: 10 +/- 5 microm, 10 microM: 14 +/- 7 microm). Smaller arteries with an initial diameter below 100 microm showed minimal or no vasodilation, while larger arteries between 100 and 120 microm had a pronounced dose-dependent effect. Systemic application of 15 mg/kg Nomega-nitro-L-arginine-methyl ester (L-NAME) completely inhibited the vasodilation. We conclude that UT-II, in contrast to most other vascular beds, is a weak NO-dependent vasodilator in the piglet pial vasculature. | lld:pubmed |
| pubmed-article:16337243 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16337243 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16337243 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16337243 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16337243 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16337243 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16337243 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16337243 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16337243 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16337243 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16337243 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16337243 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16337243 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16337243 | pubmed:month | May | lld:pubmed |
| pubmed-article:16337243 | pubmed:issn | 0024-3205 | lld:pubmed |
| pubmed-article:16337243 | pubmed:author | pubmed-author:LaczaZsomborZ | lld:pubmed |
| pubmed-article:16337243 | pubmed:author | pubmed-author:W... | lld:pubmed |
| pubmed-article:16337243 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16337243 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:16337243 | pubmed:volume | 78 | lld:pubmed |
| pubmed-article:16337243 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16337243 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16337243 | pubmed:pagination | 2763-6 | lld:pubmed |
| pubmed-article:16337243 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:16337243 | pubmed:meshHeading | pubmed-meshheading:16337243... | lld:pubmed |
| pubmed-article:16337243 | pubmed:meshHeading | pubmed-meshheading:16337243... | lld:pubmed |
| pubmed-article:16337243 | pubmed:meshHeading | pubmed-meshheading:16337243... | lld:pubmed |
| pubmed-article:16337243 | pubmed:meshHeading | pubmed-meshheading:16337243... | lld:pubmed |
| pubmed-article:16337243 | pubmed:meshHeading | pubmed-meshheading:16337243... | lld:pubmed |
| pubmed-article:16337243 | pubmed:meshHeading | pubmed-meshheading:16337243... | lld:pubmed |
| pubmed-article:16337243 | pubmed:meshHeading | pubmed-meshheading:16337243... | lld:pubmed |
| pubmed-article:16337243 | pubmed:meshHeading | pubmed-meshheading:16337243... | lld:pubmed |
| pubmed-article:16337243 | pubmed:meshHeading | pubmed-meshheading:16337243... | lld:pubmed |
| pubmed-article:16337243 | pubmed:meshHeading | pubmed-meshheading:16337243... | lld:pubmed |
| pubmed-article:16337243 | pubmed:meshHeading | pubmed-meshheading:16337243... | lld:pubmed |
| pubmed-article:16337243 | pubmed:meshHeading | pubmed-meshheading:16337243... | lld:pubmed |
| pubmed-article:16337243 | pubmed:meshHeading | pubmed-meshheading:16337243... | lld:pubmed |
| pubmed-article:16337243 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16337243 | pubmed:articleTitle | Urotensin-II is a nitric oxide-dependent vasodilator in the pial arteries of the newborn pig. | lld:pubmed |
| pubmed-article:16337243 | pubmed:affiliation | Department of Physiology/Pharmacology, Wake Forest University Health Sciences, Medical Center Blvd., Winston-Salem, NC 27157, USA. zlacza@mac.com | lld:pubmed |
| pubmed-article:16337243 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16337243 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:16337243 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16337243 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16337243 | lld:pubmed |
